logo.png
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
26 févr. 2024 14h28 HE | Oryzon Genomics, S.A.
Topline data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) reported with promising results in secondary endpoints of overall severity and control of...
logo.png
ORYZON to Provide Corporate Progress Updates at Several Events in February-March
05 févr. 2024 08h00 HE | Oryzon Genomics, S.A.
Keystone Symposia Epigenetic Mechanisms and Cancer TreatmentBio-Neuroscience17th Annual European Life Sciences CEO Forum BIO-Europe Spring 2024 MADRID, Spain and BOSTON, Feb. 05, 2024 (GLOBE...
logo.png
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
19 janv. 2024 08h00 HE | Oryzon Genomics, S.A.
MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
logo.png
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)
05 janv. 2024 15h47 HE | Oryzon Genomics, S.A.
Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th Sachs Annual Neuroscience Innovation Forum, on...
logo.png
ORYZON to Provide Corporate Progress Updates at Several Events in January
03 janv. 2024 08h00 HE | Oryzon Genomics, S.A.
7th Sachs Annual Neuroscience Innovation Forum13rd Annual LifeSci Advisors Corporate Access EventBiotech Showcase-2024 42nd Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum 2024 ...
logo.png
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
04 déc. 2023 08h00 HE | Oryzon Genomics, S.A.
To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN...
logo.png
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
21 nov. 2023 12h19 HE | Oryzon Genomics, S.A.
Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous oneTo extend its cash runway and continue the ongoing clinical trials in CNS and oncology...
logo.png
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)
07 nov. 2023 08h00 HE | Oryzon Genomics, S.A.
Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD...
logo.png
ORYZON to Provide Corporate Progress Updates at Several Events in November
06 nov. 2023 08h00 HE | Oryzon Genomics, S.A.
BIO-Europe 2023LSX Investival Showcase 2023Jefferies London Healthcare Conference 2023 MADRID, Spain and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015,...
logo.png
ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023
27 oct. 2023 12h12 HE | Oryzon Genomics, S.A.
Positive aggregate safety data from vafidemstat's fully enrolled PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials,...